Ví dụ về việc sử dụng Community-acquired trong Tiếng anh và bản dịch của chúng sang Tiếng việt
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Community-acquired pneumonia caused by S. pneumoniae or H.
Selections of antibiotics in the treatment of Community-Acquired Pneumonia based on evidence-based medicine.
Community-acquired pneumonia: 500 mg 1-2 times a day for 7-14 days;
For this reason, it is important to conduct sensitivity testing,especially in patients with community-acquired pneumonia.
Community-acquired ARF occurred in about 1% of all hospital admissions.
In vivo datasuggest that faropenem is efficacious in treating community-acquired infections including uncomplicated skin and skin structure infections;
Community-acquired pneumonia caused by methicillin-sensitive strains of Staphylococcus aureus;
A mild pneumonia in an otherwisehealthy person is likely to be a community-acquired walking pneumonia, such as that caused by Chlamydia pneumoniae.
Hospital and community-acquired infections caused by bacterial organisms sensitive to cefpirome.
Doctors often refer to pneumonia based upon the way that the infection is acquired,such as community-acquired pneumonia or hospital-acquired pneumonia.
In community-acquired pneumonia, 500 mg once or twice a day, the course lasts from 7 to 14 days;
In the United States,it was approved in October 2018 for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections.
Community-acquired pneumonia occurs when someone develops pneumonia in the community(not in a hospital).
Moxifloxacin 400 mg film-coated tablets should not be used to initiate therapy for any type of skin and skin structure infection orin severe community-acquired pneumonia.
Community-acquired pneumonia develops in people with limited or no contact with medical institutions or settings.
Solithromycin(trade name Solithera)is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia[1] and other infections.[2].
Community-acquired pneumonia(CAP) is a leading cause of hospitalization, morbidity, and mortality(1, 2).
Ceftaroline, a fifth-generation cephalosporin, is the first beta-lactam antibiotic approved in the US to treat MRSA infections in skin andsoft tissue or community-acquired pneumonia.[84].
Community-Acquired Pneumonia: This type of pneumonia is usually acquired in a public place and not in a hospital or institutional setting.
Cefditoren pivoxil is used to treat uncomplicated skin andskin structure infections, community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, pharyngitis, and tonsillitis.
Tigecycline is used to treat different kinds of bacterial infections, including complicated skin and structure infections,complicated intra-abdominal infections and community-acquired bacterial pneumonia.
This type of pneumonia is called a"community-acquired pneumonia" because it is easily passed from one member of the community to another.
Ceftobiprole(Zevtera/Mabelio) is a new 5th-generation[2] cephalosporine for the treatment of hospital-acquired pneumonia(HAP, excluding ventilator-associated pneumonia,VAP) and community-acquired pneumonia(CAP).
The compound is indicated for treating community-acquired lower respiratory tract infections(acute sinusitis, exacerbations of chronic bronchitis caused by susceptible bacteria, community-acquired pneumonia).[ 3][ 4][ 5][ 6].
The company will have to conduct new studies and clinical trials, lasting an estimated two more years,to prove the drug treats community-acquired pneumonia, bacterial sinusitis, chronic bronchitis, and skin infections.
Lefamulin(tradename Xenleta) is an antibiotic used it to treat adults with community-acquired bacterial pneumonia.[1] It is taken by mouth or by injection into a vein.[1] Relatively common side effects include diarrhea, nausea, pain at the site of injection, and liver inflammation.[1].
Nemonoxacin has completed phase 2 trials in the USA and has moved on to phase 3 trials.[4] The U.S. Food and Drug Administration(FDA) has granted nemonoxacin qualified infectious disease product(QIDP)and fast track designations for community-acquired bacterial pneumonia(CAP) and acute bacterial skin and skin-structure infections(ABSSSI).[5].
It has been approved for the treatment of uncomplicated andcomplicated urinary tract infections, community-acquired respiratory tract infections in Italy and gastroenteritis, including infectious diarrheas, in Japan.[1][6] Prulifloxacin has not been approved for use in the United States.
Levofloxacin and other fluoroquinolones have alsobeen widely used for the treatment of uncomplicated community-acquired respiratory and urinary tract infections, indications for which major medical societies generally recommend the use of older, narrower spectrum drugs to avoid fluoroquinolone resistance development.